2026年3月4日, Alnylam Execs售出320万美元库存,低于预期收入,并售出327.30美元的关闭价格。 Alnylam execs sold $3.2M in stock amid below-expected earnings and a $327.30 closing price on March 4, 2026.

2026年3月3日, Alnylam制药公司经理Pushkal Garg和Kevin Joseph Fitzgerald出售股票,Garg将股份减少7.05%,Fitzgerald减少7.03%,销售总额约320万美元。 On March 3, 2026, Alnylam Pharmaceuticals executives Pushkal Garg and Kevin Joseph Fitzgerald sold shares, with Garg reducing his stake by 7.05% and Fitzgerald by 7.03%, totaling about $3.2 million in sales. 该公司报告的第四季度收入低于估计数,其收入为1.25 EPS和11亿美元收入,比上一年增加84.9%。 The company reported fourth-quarter earnings below estimates, with $1.25 EPS and $1.10 billion in revenue, up 84.9% year-over-year. 3月4日,该股票以327.30美元关闭,分析师维持了“机动购买”评级和477.96美元目标价格。 The stock closed at $327.30 on March 4, with analysts maintaining a "Moderate Buy" rating and a $477.96 target price.